secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2025-12-10T23:59:59+00:00
Accession:  0001437749-25-037389
Event type: other
Sentiment:  neutral
Materiality: 0.05
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma stockholders elect all director nominees, ratify auditor, approve say-on-pay
--------------------------------------------------------------------------------

- All five incumbent directors reelected: Disbrow, Donofrio, Dockery, Jain, Liu with majority votes.
- Grant Thornton LLP ratified as independent auditor for fiscal 2026: 5,783,905 for, 257,411 against.
- Non-binding advisory vote on executive compensation approved: 3,193,511 for, 311,200 against.
- Approximately 60% of outstanding shares (6,083,713) present or represented at meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925037389/0001437749-25-037389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925037389/aytu20251204_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-037389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer